This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org.

This Issue's Contributors



Lisa Kennedy Sheldon, MS, ARNP, AOCNP, author of "Communication in Oncology Care: The Effectiveness of Skills Training Workshops for Healthcare Providers" (p. 305), is a doctoral student in the College of Nursing at the University of Utah in Salt Lake City and an oncology nurse practitioner in the Oncology Center at St. Joseph Hospital in Nashua, NH. According to the author, nurses should be more aware of "current"

research that explores the realm of difficult communication in the nurse-patient relationship."



Marcelle Kaplan, RN, MS, OCN®, AOCN®, primary author of "You Are Special: Recognizing the Gifts You Bring to Oncology Nursing" (p. 313), is a breast oncology clinical nurse specialist at Weill Cornell Medical Center of New York-Presbyterian Hospital in New York City. "In networking with nurses from across the country and thinking of ways to motivate them to consider positions of leadership within ONS, we realized that oncology

nurses may not be fully aware of the profound difference they make in oncology care on a daily basis," said Kaplan. "There is a real need to recognize and celebrate the unique gifts and qualities we bring to oncology nursing, each in our own special way." Coauthoring this article is Karen Taoka, RN, MN, AOCN®, the Nursing Clinical Team lead at the Queen's Medical Center in Honolulu, HI.



Ann M. Johansen, RN, BSN, OCN®, author of "Breast Cancer Chemoprevention: A Review of Selective Estrogen Receptor Modulators" (p. 317), is a staff nurse at Inland Hospital in Waterville, ME. She developed an interest in examining issues related to breast cancer chemoprevention while working toward her graduate degree. Johansen hopes that her article will help nurses understand the current status and future direction of research. "As

research on the prevention of breast cancer continues, nurses will find themselves involved in the education of patients considering preventive treatment," she said.

Kathleen Bonosky, RN, BSN, OCN®, primary author of "Hypersensitivity Reactions to Oxaliplatin: What Nurses Need to Know" (p. 325), is a nurse practitioner at the Allegheny General Hospital Cancer Center in Pittsburgh, PA. She has worked for 14 years as an oncology nurse in the outpatient setting. According to Bonosky, "Hypersensitivity reactions are a major complication in [oxaliplatin] therapy, and nurses need to be educated about the manifestations, pretreatment, and treatment modalities supported in the literature." Coauthoring this article is Rickey Miller, PharmD, BCOP, a clinical pharmacy specialist at the Allegheny General Hospital Cancer Center.

Melodie Thomas, BSN, RN, OCN®, CCRP, author of "Cetuximab: Adverse Event Profile and Recommendations for Toxicity Management" (p. 332), is a director of research nursing at the Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, in Nashville.



Julia K. Locklin, RN, MS, primary author of "Radiofrequency Ablation: A Nursing Perspective" (p. 346), is a research nurse specialist in the diagnostic radiology department at the Warren G. Magnuson Clinical Center at the National Institutes of Health in Bethesda, MD. "In working side by side with one of the nation's experts in radiofrequency ablation (RFA), it has become apparent that there is a knowledge deficit among nurses

taking care of RFA patients," said Locklin. "Calls are received in our office daily from RFA providers and nurses caring for these patients inquiring about appropriate care for patients undergoing RFA. This article is an effort to educate nurses about the RFA procedure and how to care for these patients." Coauthoring this article is Bradford J. Wood, MD, a senior clinical investigator in the diagnostic radiology department at Warren G. Magnuson Clinical Center and an adjunct investigator in the surgery branch of the National Cancer Institute in Bethesda.